Download PDF
Thromb Haemost 1992; 68(04): 413-417
DOI: 10.1055/s-0038-1646288
Original Article
Schattauer GmbH Stuttgart

Multicentric Evaluation of a New Assay for Prothrombin Fragment F1+2 Determination

H D Bruhn
1   The 1. Medizinische Klinik, Kiel, FRG
,
J Conard
2   The Hôtel-Dieu de Paris, Paris, France
,
M Mannucci
3   The Universitá di Milano, Ospedale Policlinico, Italy
,
J Monteagudo
4   The Hosp. Clinico Provincial, Barcelona, Spain
,
H Pelzer
5   The Behringwerke AG, Marburg, FRG
,
J C Reverter
4   The Hosp. Clinico Provincial, Barcelona, Spain
,
M Samama
2   The Hôtel-Dieu de Paris, Paris, France
,
A Tripodi
3   The Universitá di Milano, Ospedale Policlinico, Italy
,
C Wagner
5   The Behringwerke AG, Marburg, FRG
› Author Affiliations
Further Information

Publication History

Received 16 December 1991

Accepted after revision 04 May 1992

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A multicenter study of a recently developed ELISA for the determination of prothrombin fragment Fl+2 was performed in order to evaluate analytical and clinical aspects.

Mean intra-assay and inter-assay reproducibility were found to be 11.0 and 12.6%, respectively. The measuring range covered by the calibration curve reaches from 0.04 to 10.0 nM/1 Fl+2. Testing 133 healthy subjects a reference range of 0.37 to 1.11 nM/1 Fl+2 (2.5–97.5 percentile) with a median of 0.66 nM/1 F1+2 was calculated. Minor difficulties with blood sampling (venous occlusion for 2 min) did not affect Fl+2 plasma concentrations.

Significantly increased F1+2 levels were measured in patients with leukemia (p <0.0001), severe liver disease (p <0.005) and after myocardial infarction (p <0.01). Elevated F1+2 concentration before the beginning of heparin therapy (1.25 nM/1) decreased to 0.77 nM/1 (p <0.0001) after 1 day of therapy. For patients in the stable phase of oral anticoagulant therapy decreasing Fl+2 concentrations were measured with increasing INR. Fl+2 levels were already significantly reduced in patients with INR <2.0 (0.56 nM/1; p = 0.0005). Thus Fl+2 determination may be helpful in identifying activation processes as well as in monitoring anticoagulant therapy.

 

  • REFERENCES

  • 1 Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou M-H, Samama MM, Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988; 71: 1418-1426
    PubMedGoogle Scholar
  • 2 Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826-836
    CrossrefPubMedGoogle Scholar
  • 3 Bauer KA, Rosenberg RD. Thrombin generation in acute pro-myelocytic leukemia. Blood 1984; 64: 791-796
    PubMedGoogle Scholar
  • 4 Teitel JM, Bauer KA, Lan HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
    PubMedGoogle Scholar
  • 5 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
    PubMedGoogle Scholar
  • 6 Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80: 1535-1544
    CrossrefPubMedGoogle Scholar
  • 7 Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-159
    PubMedGoogle Scholar
  • 8 Marongin F, Sorano GG, Mameli G, Mamusa AM, Cambuli AB, Conti M, Cadoni MC, Balestrieri A. Thrombin activity and oral anticoagulant therapy: A further evaluation. Haemostasis 1990; 20: 63-64
    PubMedGoogle Scholar
  • 9 Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78: 421-424
    CrossrefPubMedGoogle Scholar
  • 10 Seitz R, Blanke H, Prätorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemostas 1988; 59: 541-542
    PubMedGoogle Scholar
  • 11 Weitz J, Cruickshank M, Thong B, Leslie B, Levine M, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700-1707
    CrossrefPubMedGoogle Scholar
  • 12 Eisenberg P, Miletich J, Sobel B, Jaffe A. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA). Thromb Haemostas 1988; 50: 707-717
    PubMedGoogle Scholar
  • 13 Eisenberg P, Miletich J. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Haemostas 1989; 55: 635-643
    PubMedGoogle Scholar
  • 14 Monteagudo J, Pereira A, Reverter JC, Pijoan J, Tusell J, Puig L, Ordinas A, Castillo R. Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Thromb Haemostas 1991; 66: 515-519
    PubMedGoogle Scholar
  • 15 Swars H, Hafner G, Erbel R, Ehrenthal W, Rupprecht HJ, Prellwitz W, Meyer J. Prothrombin fragments and thrombotic occlusion of coronary stents. Lancet 1991; 337: 59-60
    PubMedGoogle Scholar
  • 16 Mannucci PM, Tripodi A, Bottasso B, Baudo F, Finazzi G, De Stefano V, Palareti G, Manotti C, Mazzucconi MG, Rodeghiero F. Markers of procaogulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemostas 1992; 67: 200-202
    PubMedGoogle Scholar